Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 078 Randomised Phase 3 Clinical Trial

Yi-Long Wu,Shun Lu,Ying Cheng,Caicun Zhou,Jie Wang,Tony Mok,Li Zhang,Haiyan Tu,Lin Wu,Jifeng Feng,Yiping Zhang,Alexander Valeriercich Luft,Jianying Zhou,Zhiyong Ma,You Lu,Chengping Hu,Yuankai Shi,Christine Baudelet,Zoe Li,Jianhua Chang
DOI: https://doi.org/10.2139/ssrn.3244996
2018-01-01
Abstract:BACKGROUND: Data on immuno-oncology agents in Chinese patients are limited despite a need for new therapies. We evaluated the efficacy and safety of nivolumab in a predominantly Chinese patient population with previously treated non-small-cell lung cancer (NSCLC).
What problem does this paper attempt to address?